Cargando…
Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy
OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981429/ https://www.ncbi.nlm.nih.gov/pubmed/35037389 http://dx.doi.org/10.1111/cns.13796 |
_version_ | 1784681601998782464 |
---|---|
author | Yin, Xiaotong Liu, Yan Guo, Yang Zhao, Limei Li, Guofei Tan, Xiaoping |
author_facet | Yin, Xiaotong Liu, Yan Guo, Yang Zhao, Limei Li, Guofei Tan, Xiaoping |
author_sort | Yin, Xiaotong |
collection | PubMed |
description | OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were enrolled. Data on seizure activity and types, daily dose, and AEDs blood levels were derived from routine clinical follow‐up. Changes in AEDs clearance were compared between each trimester and nonpregnant baseline. The ratio of AED levels of each trimester to their targets (nonpregnant baseline) concentrations (RTC) was compared between patients with and without an increased seizure. A binary logistic regression was used to investigate the risk factors contributing to seizure worsening during pregnancy. RESULTS: Increased clearances of LTG, LEV, and OXC were observed in all trimesters versus nonpregnant baseline. The peak changes in the clearance of LTG (3.42‐fold baseline clearance) (p < 0.001) and LEV (2.78‐fold) (p < 0.001) occurred in the second trimester during pregnancy, followed by oxcarbazepine (2.11‐fold) in the third trimester (p < 0.03). Plasma concentrations of LTG and LEV during pregnancy were significantly decreased compared to baseline levels, except for OXC. However, no significant differences in RTC values were observed between patients with and without seizure worsening. Some risk factors as seizures for the prior nine months could significantly affect seizure frequency during pregnancy. CONCLUSION: We found substantial changes in the pharmacokinetics of multiple newer AEDs in WWE, reinforcing the need for therapeutic drug monitoring (TDM) during pregnancy. We would encourage at least one monitoring every trimester and probably more frequently for women with poorly seizure control before pregnancy, and AEDs dose adjustment should keep up with clearance changes. In addition, a well‐controlled seizure nine months before pregnancy could lower the risks of seizure during pregnancy, highlighting the importance of pre‐pregnancy counseling and seizure management before pregnancy. |
format | Online Article Text |
id | pubmed-8981429 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89814292022-04-11 Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy Yin, Xiaotong Liu, Yan Guo, Yang Zhao, Limei Li, Guofei Tan, Xiaoping CNS Neurosci Ther Original Articles OBJECTIVE: To investigate pharmacokinetic changes in newer antiepileptic drugs (AEDs) and assess seizure frequencies and risk factors of increased seizures during pregnancy in women with epilepsy (WWE). METHODS: A total of 56 pregnancies in 53 WWE who received newer antiepileptic drugs (AEDs) were enrolled. Data on seizure activity and types, daily dose, and AEDs blood levels were derived from routine clinical follow‐up. Changes in AEDs clearance were compared between each trimester and nonpregnant baseline. The ratio of AED levels of each trimester to their targets (nonpregnant baseline) concentrations (RTC) was compared between patients with and without an increased seizure. A binary logistic regression was used to investigate the risk factors contributing to seizure worsening during pregnancy. RESULTS: Increased clearances of LTG, LEV, and OXC were observed in all trimesters versus nonpregnant baseline. The peak changes in the clearance of LTG (3.42‐fold baseline clearance) (p < 0.001) and LEV (2.78‐fold) (p < 0.001) occurred in the second trimester during pregnancy, followed by oxcarbazepine (2.11‐fold) in the third trimester (p < 0.03). Plasma concentrations of LTG and LEV during pregnancy were significantly decreased compared to baseline levels, except for OXC. However, no significant differences in RTC values were observed between patients with and without seizure worsening. Some risk factors as seizures for the prior nine months could significantly affect seizure frequency during pregnancy. CONCLUSION: We found substantial changes in the pharmacokinetics of multiple newer AEDs in WWE, reinforcing the need for therapeutic drug monitoring (TDM) during pregnancy. We would encourage at least one monitoring every trimester and probably more frequently for women with poorly seizure control before pregnancy, and AEDs dose adjustment should keep up with clearance changes. In addition, a well‐controlled seizure nine months before pregnancy could lower the risks of seizure during pregnancy, highlighting the importance of pre‐pregnancy counseling and seizure management before pregnancy. John Wiley and Sons Inc. 2022-01-17 /pmc/articles/PMC8981429/ /pubmed/35037389 http://dx.doi.org/10.1111/cns.13796 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Yin, Xiaotong Liu, Yan Guo, Yang Zhao, Limei Li, Guofei Tan, Xiaoping Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title | Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title_full | Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title_fullStr | Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title_full_unstemmed | Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title_short | Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
title_sort | pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981429/ https://www.ncbi.nlm.nih.gov/pubmed/35037389 http://dx.doi.org/10.1111/cns.13796 |
work_keys_str_mv | AT yinxiaotong pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy AT liuyan pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy AT guoyang pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy AT zhaolimei pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy AT liguofei pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy AT tanxiaoping pharmacokineticchangesfornewerantiepilepticdrugsandseizurecontrolduringpregnancy |